Werewolf Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
HOWL$1.010.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(amounts in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $110,995 | $134,343 |
| Prepaid expenses and other current assets | 2,071 | 2,677 |
| Other receivables | — | 1,350 |
| Total current assets | 113,066 | 138,370 |
| Property and equipment, net | 6,322 | 7,958 |
| Restricted cash and cash equivalents, net of current portion | 1,220 | 21,023 |
| Operating lease right of use asset | 6,001 | 6,888 |
| Other assets | 320 | 594 |
| Total assets | $126,929 | $174,833 |
| Liabilities and stockholders’ equity: | ||
| Current liabilities: | ||
| Accounts payable | $3,035 | $1,336 |
| Accrued expenses and other current liabilities | 10,588 | 8,860 |
| Operating lease liability, current | 1,557 | 1,608 |
| Deferred revenue, current | — | 907 |
| Note payable, current | — | 6,667 |
| Total current liabilities | 15,180 | 19,378 |
| Operating lease liability, net of current portion | 9,435 | 10,992 |
| Deferred revenue, net of current portion | — | 433 |
| Note payable, net of discount, issuance costs, and current portion | 26,095 | 32,656 |
| Derivative liability | 2,829 | — |
| Total liabilities | 53,539 | 63,459 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 5,000,000 shares authorized as of December 31, 2024 and 2023; no shares issued or outstanding as of December 31, 2024 and 2023 | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized as of December 31, 2024 and 2023; 44,827,159 and 39,107,048 shares issued as of December 31, 2024 and 2023, respectively; 44,827,159 and 39,107,048 shares outstanding as of December 31, 2024 and 2023, respectively | 5 | 4 |
| Additional paid-in capital | 487,973 | 455,443 |
| Accumulated deficit | (414,588) | (344,073) |
| Total stockholders’ equity | 73,390 | 111,374 |
| Total liabilities and stockholders’ equity | $126,929 | $174,833 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.